The study objective and statistical analysis of quality of life assessment are changed; Reporting of pregnancies is added; The grading of acute GvHD is corrected.

Change of principal investigator; The registration of patients receiving a T-cell depleted allogenic SCT was added; An extra inclusion criterion for the second randomization was added; dose adjustment of cyclosporin A was added; deletion of a off protocol reason (infusion of donor lymphocytes);

Change of principal investigator; Deletion of the section 'severe GvHD; The registration of patients receiving a T-cell depleted allogeneic SCT and that will be treated with immunosuppression according to local hospital policy is deleted form protocol. It was added in version 3, but has not been implemented; correction with regards to reporting of GvHD; Information requested at registering patient is corrected from “patient’s initials or code” into “local patient code (optional)”.

Addition of an additional treatment arm with a short-course post-transplant GVHD prophylaxis consisting of high-dose cyclophosphamide. (introduction, objectives, study design, treatment, statistical considerations); Changed inclusion criterion regarding age; Changes in reason for going off protocol treatment with regards to development of GVHD; Added is the use of a Summary of Product Characteristics (SPC) for an authorized medicinal product in the definition of SUSAR.

• Arm 3 Post transplant cyclophosphamide: Cyclosporine A treatment is extended to +70 days • Arm 3: Added option of cyclosporine A p.o. dose. • Arm 1 and 2: Date start cyclosporine A is changed to day -5 –day -3 (depending on local procedures). • Period of reporting adverse events is corrected (in accordance to earlier amendment • Exemptions of SAE reporting are clarified • Exemption of SAE reporting of chronic GvHD is limited to chronic GvHD not requiring systemic treatment. • Added is a monitoring of overall mortality to detect possible differences in relapse rate between arm 1 and arm 3.